Bleakley Financial Group LLC Acquires Shares of 3,716 Disc Medicine, Inc. (NASDAQ:IRON)

Bleakley Financial Group LLC acquired a new stake in Disc Medicine, Inc. (NASDAQ:IRON) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 3,716 shares of the company’s stock, valued at approximately $215,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. bought a new stake in Disc Medicine in the fourth quarter valued at approximately $161,000. Legato Capital Management LLC bought a new stake in Disc Medicine in the fourth quarter valued at approximately $305,000. SG Americas Securities LLC bought a new stake in Disc Medicine in the fourth quarter valued at approximately $528,000. Vanguard Group Inc. lifted its position in Disc Medicine by 18.9% in the third quarter. Vanguard Group Inc. now owns 665,452 shares of the company’s stock valued at $31,263,000 after purchasing an additional 105,685 shares during the last quarter. Finally, Hudson Bay Capital Management LP bought a new stake in Disc Medicine in the third quarter valued at approximately $1,973,000. Institutional investors own 83.70% of the company’s stock.

Insiders Place Their Bets

In other Disc Medicine news, major shareholder Venture Fund X. L.P. Atlas sold 47,500 shares of the stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $67.65, for a total value of $3,213,375.00. Following the completion of the transaction, the insider now owns 1,402,186 shares in the company, valued at $94,857,882.90. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director William Richard White sold 2,560 shares of the stock in a transaction on Thursday, April 11th. The stock was sold at an average price of $31.80, for a total value of $81,408.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Venture Fund X. L.P. Atlas sold 47,500 shares of the stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $67.65, for a total value of $3,213,375.00. Following the completion of the sale, the insider now directly owns 1,402,186 shares in the company, valued at $94,857,882.90. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 152,560 shares of company stock worth $10,228,908. 4.71% of the stock is owned by corporate insiders.

Analyst Ratings Changes

IRON has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Disc Medicine in a report on Monday, April 1st. Cantor Fitzgerald restated an “overweight” rating and set a $85.00 target price on shares of Disc Medicine in a report on Wednesday, December 20th. BMO Capital Markets decreased their target price on Disc Medicine from $80.00 to $50.00 and set an “outperform” rating for the company in a report on Tuesday, April 2nd. Raymond James restated an “outperform” rating and set a $40.00 target price (down previously from $75.00) on shares of Disc Medicine in a report on Monday, April 1st. Finally, Wedbush restated an “outperform” rating and set a $43.00 target price (down previously from $84.00) on shares of Disc Medicine in a report on Monday, April 1st. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.29.

Disc Medicine Trading Down 1.9 %

IRON opened at $29.93 on Wednesday. The stock has a fifty day simple moving average of $57.21 and a two-hundred day simple moving average of $55.74. The company has a market cap of $722.51 million, a price-to-earnings ratio of -8.58 and a beta of 0.18. Disc Medicine, Inc. has a 12-month low of $21.70 and a 12-month high of $77.60.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.22). On average, analysts predict that Disc Medicine, Inc. will post -4.44 EPS for the current year.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.